Olema Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Olema Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 10% ve 65.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 16.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -104.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

10.0%

Kazanç büyüme oranı

16.42%

EPS büyüme oranı

Biotechs kazanç büyümesi	29.1%
Gelir büyüme oranı	65.1%
Gelecekteki özkaynak getirisi	-104.06%
Analist kapsamı	Good
Son güncelleme	14 Sep 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Seeking Alpha • Sep 09

Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1 '27

Summary Olema Pharmaceuticals, Inc. is advancing palazestrant, a next-generation SERD, in two pivotal Phase 3 trials for ER+/HER2- metastatic breast cancer. Palazestrant claims best-in-class efficacy in both ESR1 mutant and wild-type tumors, but safety concerns, notably neutropenia, require validation in larger studies. Intense competition from multiple recently approved SERDs and delayed Phase 3 data (now Q1 2027) temper near-term upside for OLMA. I maintain a Hold rating on OLMA, as the current valuation reflects both potential and significant execution risks ahead of key catalysts. Read the full article on Seeking Alpha

Seeking Alpha • Apr 08

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Summary Olema Pharmaceuticals's palazestrant shows promise in late-stage trials for metastatic breast cancer, with potential FDA approval and commercial launch by 2027. Strong liquidity with $139.5 million in cash and $294.6 million in marketable securities, providing a cash runway of 4-4.5 years. Despite competition in the SERD space, OLMA's valuation is low at $200 million, suggesting potential for significant upside. The long-term outlook is positive, with OLMA positioned to deliver a reliable income-generating drug, making the current valuation a potential bargain. Read the full article on Seeking Alpha

Seeking Alpha • Feb 17

Olema Pharmaceuticals: Interesting But Undifferentiated Data

Summary Olema Pharmaceuticals is developing palazestrant, an oral SERD in phase 3 trials for ER+/HER2- metastatic breast cancer, with promising early data in combination with ribociclib. Despite positive early-stage data, OLMA's phase 3 trial is open-label, making it difficult to position the molecule in a competitive market. Financially, OLMA has a solid cash runway of 11–18 quarters, but the ESR1+ mBC market is small with dominant existing players. I remain cautious about OLMA stock as an investment, awaiting more conclusive phase 3 data to better gauge its competitive positioning. Read the full article on Seeking Alpha

Seeking Alpha • Dec 02

Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward

Summary Olema Pharmaceuticals, Inc. entered into an agreement with Novartis to obtain KISQALI supply for the soon-to-be initiated phase 3 OPERA-02 study, targeting patients with ER+/HER2- metastatic breast cancer; Study to start mid-2025. Data from ongoing phase 3 OPERA-01 study, using palazestrant alone as a monotherapy to target patients with ER+/HER2- metastatic breast cancer, expected in 2026. The global breast cancer market size is predicted to surpass $89.01 billion by 2034. An IND Filing for KAT6 inhibitor OP-3136 to treat breast cancer patients is expected to happen in Q4 of 2024, with a phase 1 study being initiated in 2025. Read the full article on Seeking Alpha

Analiz Makalesi • Aug 29

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Jun 17

Olema Pharmaceuticals: Still Merits A Small Holding

Summary Olema Pharmaceuticals is focused on developing palazestrant and OP-3136 for women with cancer, with FDA Fast Track designation for palazestrant. Palazestrant is currently being evaluated in a Phase 3 clinical trial for ER+/HER2- advanced or metastatic breast cancer and as part of combination therapies. Analyst firms have reissued Buy ratings for Olema in June following trial updates, and the company's balance sheet is solid for now. An updated analysis around Olema Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha

Analiz Makalesi • May 11

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Mar 28

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Summary OLEMA Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted oncology therapies, with a focus on women's cancer. Their flagship drug, palazestrant, shows promising results for halting the progression of estrogen receptor-positive and HER2-negative breast cancer. The company has collaborations with Novartis and Pfizer and expects trial updates in 2024, but tangible FDA approvals and revenues are still a long way off. Despite promising developments, the long FDA approval and revenue generation timeline warrants a “hold” rating. Read the full article on Seeking Alpha

Analiz Makalesi • Mar 04

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Key Insights Olema Pharmaceuticals' estimated fair value is US$14.37 based on 2 Stage Free Cash Flow to Equity Olema...

Analiz Makalesi • Nov 09

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Olema Pharmaceuticals...

Analiz Makalesi • Jun 11

We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:OLMA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	91	-268	-219	-234	8
12/31/2027	6	-294	-258	-221	9
12/31/2026	N/A	-246	-201	-188	8
6/30/2026	N/A	-205	-165	-165	N/A
3/31/2026	N/A	-185	-149	-149	N/A
12/31/2025	N/A	-162	-147	-147	N/A
9/30/2025	N/A	-150	-135	-135	N/A
6/30/2025	N/A	-142	-127	-127	N/A
3/31/2025	N/A	-129	-125	-125	N/A
12/31/2024	N/A	-129	-105	-104	N/A
9/30/2024	N/A	-123	-97	-97	N/A
6/30/2024	N/A	-110	-92	-92	N/A
3/31/2024	N/A	-99	-87	-87	N/A
12/31/2023	N/A	-97	-84	-84	N/A
9/30/2023	N/A	-96	-85	-85	N/A
6/30/2023	N/A	-97	-81	-80	N/A
3/31/2023	N/A	-110	-85	-85	N/A
12/31/2022	N/A	-105	-82	-82	N/A
9/30/2022	N/A	-100	-82	-81	N/A
6/30/2022	N/A	-95	-76	-75	N/A
3/31/2022	N/A	-79	-59	-58	N/A
12/31/2021	N/A	-71	-52	-51	N/A
9/30/2021	N/A	-60	-42	-41	N/A
6/30/2021	N/A	-52	-37	-37	N/A
3/31/2021	N/A	-38	-29	-29	N/A
12/31/2020	N/A	-24	-20	-20	N/A
9/30/2020	N/A	-15	-12	-12	N/A
12/31/2019	N/A	-4	N/A	-3	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: OLMA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: OLMA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: OLMA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: OLMA şirketinin gelirinin (yıllık 65.1% ) US pazarından (yıllık 13.3% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: OLMA şirketinin gelirinin (yıllık 65.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: OLMA 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/16 00:01
Gün Sonu Hisse Fiyatı	2026/09/16 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Olema Pharmaceuticals, Inc. 18 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Arlinda Lee	Canaccord Genuity
Naureen Quibria	Capital One Securities, Inc.
Zegbeh Jallah	Capital One Securities, Inc.

Olema Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 10% to US$36.50

Price target increased by 10% to US$27.25

Price target decreased by 7.1% to US$26.00

Price target increased by 13% to US$24.43

Recent updates

Price target decreased by 10% to US$36.50

Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1 '27

Olema Pharmaceuticals, Inc. Announces the Appointment of Jason O’Byrne as Principal Financial Officer and Principal Accounting Officer, Effective August 11, 2026

Independent Director recently sold US$291k worth of stock

Independent Director notifies of intention to sell stock

Olema Pharmaceuticals, Inc. Announces Initial Clinical Data for Op-3136 and Provides Update on Product Pipeline

Olema Reports Encouraging Early Data for OP-3136 and Advances Phase 3 Palazestrant Trial

Olema Pharmaceuticals, Inc. Appoints Prakash Raman, Ph.D., to Board of Directors

Insufficient new directors

Olema Pharmaceuticals, Inc. Announces Preclinical Data for Palazestrant and Op-3136

New minor risk - Shareholder dilution

Now 37% undervalued after recent price drop

Insider notifies of intention to sell stock

Consultant notifies of intention to sell stock

Now 20% undervalued

Olema Pharmaceuticals, Inc. Announces Executive Changes, Effective January 30, 2026

Insider recently sold US$283k worth of stock

Chief Medical Officer recently sold US$3.6m worth of stock

Independent Chairperson of the Board notifies of intention to sell stock

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Olema Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $190 million.

Price target increased by 10% to US$27.25

New major risk - Revenue and earnings growth

Olema Pharmaceuticals, Inc. to Present Trial-In-Progress Poster for Phase 3 Operation-In- Progress Poster for Phase 3 Operation-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025

Olema Pharmaceuticals, Inc. Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

New major risk - Revenue and earnings growth

Director recently sold US$205k worth of stock

Director notifies of intention to sell stock

Olema Pharmaceuticals, Inc. Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) dropped from Russell 2500 Growth Index

New minor risk - Share price stability

Olema Pharmaceuticals, Inc. Announces Palazestrant Dose Selection and Trial-In-Progress Poster at ASCO 2025 Annual Meeting

Olema Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2025

Olema Pharmaceuticals, Inc. Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models At AACR 2025

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Price target decreased by 7.1% to US$26.00

Olema Pharmaceuticals, Inc. Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

Olema Pharmaceuticals: Interesting But Undifferentiated Data

New major risk - Shareholder dilution

Olema Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Chief Medical Officer exercised options to buy US$85k worth of stock.

President recently sold US$986k worth of stock

New minor risk - Share price stability

Olema Pharmaceuticals, Inc. announced that it has received $249.999225 million in funding from a group of investors

President notifies of intention to sell stock

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib At the San Antonio Breast Cancer Symposium

Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward

Chief Operating & Financial Officer exercised options to buy US$207k worth of stock.

New major risk - Revenue and earnings growth

Olema Oncology Announces New Preclinical Combination Data to Be Presented At the 2024 Eortc-Nci-Aacr Symposium on Molecular Targets and Cancer Therapeutics

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

New major risk - Revenue and earnings growth

Director notifies of intention to sell stock

Olema Pharmaceuticals: Still Merits A Small Holding

Director notifies of intention to sell stock

Olema Pharmaceuticals, Inc. Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 Esmo Breast Cancer Congress

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Director notifies of intention to sell stock

Insufficient new directors

Olema Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Director notifies of intention to sell stock

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant Er+ Breast Cancer Both as Monotherapy and in Combination with Cdk4/6 Inhibitors

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Director notifies of intention to sell stock

Chief Medical Officer exercised options to buy US$241k worth of stock.

Chief Operating & Financial Officer exercised options to buy US$563k worth of stock.

Olema Pharmaceuticals, Inc. Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Director notifies of intention to sell stock